八旬患者机器人辅助根治性膀胱切除联合体内尿流改道的并发症与死亡率
基于欧洲10中心1890例接受机器人辅助根治性膀胱切除联合体内尿流改道的膀胱癌患者回顾性分析,比较≥80岁与<80岁患者的并发症与死亡率。≥80岁组90天高级别并发症率13%低于<80岁组21%,非癌相关90天死亡率两组相当,但≥80岁组12个月癌症特异性死亡率和其他原因死亡率均更高。
要点
- 高龄(≥80岁)不是高级别并发症的独立预测因素。
- ≥80岁组90天非癌相关死亡率与<80岁组相当。
- ≥80岁组术后1年其他原因死亡率升高需关注。
核心结论
- 经过筛选的≥80岁膀胱癌患者接受机器人辅助根治性膀胱切除联合体内尿流改道,高级别并发症率可接受。
- 术后90天死亡率主要由癌症进展驱动,非癌相关死亡率与<80岁患者相当。
- ≥80岁组术后第一年其他原因死亡率升高应予以考虑。
研究设计与样本
- 回顾性分析2004至2018年欧洲10个中心连续1890例因膀胱癌行机器人辅助根治性膀胱切除联合体内尿流改道的患者。
- 比较<80岁(1726例)与≥80岁(164例)患者的术后并发症(Clavien-Dindo分级)和死亡率。
- 采用非参数Aalen-Johansen估计量计算癌症特异性死亡和其他原因死亡。
主要发现
- <80岁组30天和90天高级别(Clavien-Dindo III-V级)并发症率分别为15%和21%,≥80岁组分别为11%和13%(P=0.2和P=0.03)。
- 多变量logistic回归调整术前术后变量后,年龄≥80岁不是高级别并发症的独立预测因素(OR 0.6,95%CI 0.3-1.1;P=0.12)。
- 非癌相关90天死亡率≥80岁组为2.3%,<80岁组为1.8%(P=0.7)。
- 估计12个月癌症特异性死亡率<80岁组为8%,≥80岁组为15%(P=0.009);其他原因死亡率分别为3%和8%(P<0.001)。
临床怎么用
- 为经过筛选的≥80岁膀胱癌患者选择机器人辅助根治性膀胱切除联合体内尿流改道时,可参考本研究的并发症与死亡率数据。
- 术前咨询应平衡癌症相关风险与治疗相关风险,并告知高龄患者术后第一年其他原因死亡率可能升高。
局限性
- 回顾性研究设计。
- ≥80岁组样本量较小(164例)。
- 仅纳入经过筛选的老年患者,结论可能不适用于所有高龄人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the postoperative complication and mortality rate following laparoscopic radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD) in octogenarians. PATIENTS AND METHODS: We conducted a retrospective analysis comparing postoperative complication and mortality rates depending on age in a consecutive series of 1890 patients who underwent RARC with ICUD for bladder cancer between 2004 and 2018 in 10 European centres. Outcomes of patients aged <80 years and those aged ≥80 years were compared with regard to postoperative complications (Clavien-Dindo grading) and mortality rate. Cancer-specific mortality (CSM) and other-cause mortality (OCM) after surgery were calculated using the non-parametric Aalen-Johansen estimator. RESULTS: A total of 1726 patients aged <80 years and 164 aged ≥80 years were included in the analysis. The 30- and 90-day rate for high-grade (Clavien-Dindo grades III-V) complications were 15% and 21% for patients aged <80 years compared to 11% and 13% for patients aged ≥80 years (P = 0.2 and P = 0.03), respectively. In a multivariable logistic regression analysis adjusting for pre- and postoperative variables, age ≥80 years was not an independent predictor of high-grade complications (odds ratio 0.6, 95% confidence interval 0.3-1.1; P = 0.12). The non-cancer-related 90-day mortality was 2.3% for patients aged ≥80 years and 1.8% for those aged <80 years, respectively (P = 0.7). The estimated 12-month CSM and OCM rates for those aged <80 years were 8% and 3%, and for those aged ≥80 years, 15% and 8%, respectively (P = 0.009 and P < 0.001). CONCLUSIONS: The minimally invasive approach to RARC with ICUD for bladder cancer in well-selected elderly patients (aged ≥80 years) achieved a tolerable high-grade complication rate; the 90-day postoperative mortality rate was driven by cancer progression and the non-cancer-related rate was equivalent to that of patients aged <80 years. However, an increased OCM rate in this elderly group after the first year should be taken into account. These results will support clinicians and patients when balancing cancer-related vs treatment-related risks and benefits.
引用
- Mortezavi A, Crippa A, Edeling S, et al. Morbidity and mortality after robot-assisted radical cystectomy with intracorporeal urinary diversion in octogenarians: results from the European Association of Urology Robotic Urology Section Scientific Working Group. BJU Int. 2020. PMID: 33058469. doi:10.1111/bju.15274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。